zars-pharma.jpgZARS Pharma has announced that FDA has approved a topical local anesthetic peel developed under the name of S-Caine Peel (Lidocaine and Tetracaine) 7% / 7% cream. The product would be applied to locally anesthetized skin before various superficial dermatological procedures such as dermal filler procedure, pulsed dye laser therapy, facial laser resurfacing, and laser- assisted tattoo removal. This product is expected to provide physicians with a new option in reducing patients' pain associated with common cosmetic and aesthetic procedures. In clinical trials, the most common side effects were local skin reactions, such as erythema, blanching and edema. The Lidocaine and Tetracaine 7% / 7% cream should not be used for a duration longer than recommended, and is contraindicated in patients with a known history of sensitivity to lidocaine, Tetracaine, or local anesthetics of the amide or ester type.